外源的爱斯坦-巴尔病毒核抗原1诱导ADAR1驱动的瘤抵抗免疫治疗
Changlin Liu1,2, Zhiqiang Sun3,4, Chao Li5
1Shenzhen Key Laboratory of Viral Oncology, Shenzhen Hospital of Southern Medical University, Guangdong, China.
Signal transduction and targeted therapy
|February 17, 2026
概括
爱斯坦-巴尔病毒蛋白EBNA1通过增强RNA编辑来抑制抗瘤免疫力,阻碍干扰素反应. 用EP-1215准EBNA1,恢复免疫力,改善对检查点阻塞疗法的反应.
科学领域:
- 在瘤学瘤学.
- 病毒学 病毒学
- 免疫学 免疫学 免疫学
背景情况:
- 免疫检查点阻塞 (ICB) 治疗受到瘤抵抗的限制,通常涉及抑制的干扰素 (IFN) 信号传递.
- 病毒病原体与这种免疫抑制有关,但机制尚未完全理解.
研究的目的:
- 调查爱斯坦-巴尔病毒编码的EBNA1在瘤免疫抑制中的作用及其与RNA编辑的联系.
- 探索针对EBNA1作为提高ICB治疗疗效的策略.
主要方法:
- 在小鼠中的比较瘤模型分析.
- 研究了EBNA1与IGF2BP3和EIF4G1的相互作用,以增强ADAR1的翻译.
- 评估EBNA1和ADAR1对IFN信号传递和T细胞透的影响.
- 评估了将一个针对EBNA1的PROTAC降解剂 (EP-1215) 与抗PD-1治疗相结合的疗效.
主要成果:
- 过度表达EBNA1抑制了CD8+T细胞的透,抑制了IFN反应,促进了M2巨细胞的两极分化,加速了瘤的生长.
- EBNA1增强了ADAR1的翻译,导致IFN相关基因附近的dsRNA的RNA编辑增加,掩盖了免疫刺激信号.
- 结合EP-1215和抗PD-1疗法恢复了IFN信号传输,增加了T细胞透,并抑制了人性化小鼠的EBNA1+瘤.
结论:
- 病毒蛋白EBNA1通过劫持RNA编辑机器 (ADAR1) 来抑制IFN反应来驱动瘤免疫抑制.
- 向EBNA1代表了一种潜在的治疗策略,通过将"冷"瘤转化为免疫学上"热"的瘤来克服对ICB治疗的耐药性.
更多相关视频
08:52Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
Published on: May 27, 2011
17.8K
09:43An Efficient and Simple Method to Establish NK and T Cell Lines from Patients with Chronic Active Epstein-Barr Virus Infection
Published on: March 30, 2018
9.7K
相关概念视频
Tumor Immunotherapy
2.0K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K
Mechanisms of Retrovirus-induced Cancers
7.0K
Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
7.0K
Mitogens and the Cell Cycle
8.2K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K
Adaptive Mechanisms in Cancer Cells
7.2K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.2K
Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
